3D medical background with DNA strands
3D medical background with DNA strands
Slide background

Publicaties

(03-Jun-2019; versie 3: Publicaties i.h.k.v. CPCT t/m 03-Jun-2019)

Ausems MGEM, Oosterwijk JC, Nielsen M, Lolkema MP, Hoogerbrugge N, Ligtenberg MJL.

Genetic testing in patients with cancer, new developments

Ned Tijdschr Geneeskd. 2019 May; 20: 163. pii: D3801.https://www.ncbi.nlm.nih.gov/m/pubmed/31140768/?i=1&from=[Genetic testing in patients with cancer; new developments].

2019
Giesbertz NAA, van Harten MH, Bredenoord AL.

A duty of recontact in genetics: context matters

Nature Reviews Genetics (2019). 2019 Apr; 1. https://doi.org/10.1038/s41576-019-0121-7

2019
Bijlsma RM, Wouters RHP, Wessels H, May AM, Ausems MGEM, Voest EE, Bredenoord AL.

Managing unsolicited findings in genomics: A qualitative interview study with cancer patients.

Psychooncology. 2018 Apr;27(4):1327-1333. doi: 10.1002/pon.4676. Epub 2018 Mar 24.

2018
Bijlsma RM, Wessels H, Wouters RHP, May AM, Ausems MGEM, Voest EE, Bredenoord AL.

Cancer patients’ intentions towards receiving unsolicited genetic information obtained using next-generation sequencing.

Fam Cancer. 2018 Apr;17(2):309-316. doi: 10.1007/s10689-017-0033-7.

2018
Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

2017
Bins S, Cirkel GA, Gadellaa-van Hooijdonk CG, Weeber F, Nijman IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

Oncologist. 2016 Sep 23. pii: theoncologist.2016-0085. [Epub ahead of print]

http://theoncologist.alphamedpress.org/content/early/2016/09/23/theoncologist.2016-0085.abstract

2016
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE

The Time To Progression Ratio: a new individualized volumetric parameter for early detection of clinical benefit of targeted therapies

Ann Oncol. 2016 May 27. pii: mdw223

2016
Rhodé M Bijlsma, Annelien L Bredenoord, Christa G Gadellaa-Hooijdonk, Martijn PJ Lolkema, Stefan Sleijfer, Emile E Voest, Margreet GEM Ausems and Neeltje Steeghs

Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered

European Journal of Human Genetics , (13 April 2016) | doi:10.1038/ejhg.2016.27

2016
de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, Willems SM, Lolkema MP

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

PLoS One. 2016 Feb 26;11(2):e0149405. doi: 10.1371/journal.pone.0149405

2016
Hoogstraat M1, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, Voest EE, Lolkema MP.

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.

Pigment Cell Melanoma Res. 2015 May;28(3):318-23. doi: 10.1111/pcmr.12347. Epub 2015 Jan 7.

2015
Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, Rottenberg S, Wessels LF, Adams DJ, Peeper DS, Krijgsman O.

CopywriteR: DNA copy number detection from off-target sequence data.

Genome Biol. 2015 Feb 27;16:49. doi: 10.1186/s13059-015-0617-1.

2015
Marlous Hoogstraat, John W J Hinrichs, Nicolle J M Besselink, Joyce H Radersma-van Loon, Carmen M A de Voijs, Ton Peeters, Isaac J Nijman, Roel A de Weger, Emile E Voest, Stefan M Willems, Edwin Cuppen, Marco J Koudijs

Simultaneous detection of clinically relevant mutations and amplifications for cancer diagnostics using Next Generation Sequencing.

J Mol Diagn 2015 Jan 24;17(1):10-8. Epub 2014 Oct 24.

2015
Hoogstraat M, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, Voest EE, Lolkema MP.

Detailed imaging and genetic analysis reveal a secondary BRAFL 505H resistance mutation and extensive intra-patient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.

Pigment Cell Melanoma Res. 2014 Dec 17. doi: 10.1111/pcmr.12347.

2014
Geert A Cirkel, Christa G Gadellaa-van Hooijdonk, Marco J Koudijs, Stefan M Willems, Emile E Voest

Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?

Future Oncol 2014 Feb;10(3):417-28

2014
Sander Bins, Jan H.M. Schellens, Emile E. Voest, Stefan Sleijfer

Geneesmiddelenonderzoek in de Oncologie, vorderingen in het genoomtijdperk

Nederlands Tijdschrift voor Geneeskunde, 2014;158:A6801

2014
Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J.

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

PLoS One. 2014 Sep 17;9(9):e103988. doi: 10.1371/journal.pone.0103988. eCollection 2014.

2013
Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC, Nijman IJ, Guy T, van ’t Slot R, Jonges TN, Lolkema MP, Koudijs MJ, Zweemer RP, Voest EE, Cuppen E, Kloosterman WP.

 

The genomic and transcriptomic dynamics of treatment-naïve epithelial ovarian cancer

Genome Res. 2014 Feb;24(2):200-11. doi: 10.1101/gr.161026.113. Epub 2013 Nov 12.

2013
Lolkema MP, Gadellaa-van Hooijdonk CG, Bredenoord AL, Kapitein P, Roach N, Cuppen E, Knoers NV, Voest EE.

Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology.

J Clin Oncol. 2013 May 20;31(15):1842-8.

2013
Lips E, Magali M, Mulder L. et al.
Next-generation sequencing to find predictors for chemotherapy response in triple-negative breast cancer.
J Clin Oncol 31, 2013 (suppl; abstr 1010)
2013
Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, Roessingh WM, Lansu N, de Bruijn E, van Hillegersberg R, van Diest PJ, Cuppen E, Voest EE.

Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.

Clin Cancer Res. 2012 Feb 1;18(3):688-99.

2012
Harakalova M, Mokry M, Hrdlickova B, Renkens I, Duran K, van Roekel H, Lansu N, van Roosmalen M, de Bruijn E, Nijman IJ, Kloosterman WP, Cuppen E

Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing.

Nat Protoc. 2011 Nov 3;6(12):1870-86

2011
Kloosterman WP, Hoogstraat M, Paling O, Tavakoli-Yaraki M, Renkens I, Vermaat JS, van Roosmalen MJ, van Lieshout S, Nijman IJ, Roessingh W, van ’t Slot R, van de Belt J, Guryev V, Koudijs M, Voest E, Cuppen E

Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.

Genome Biol. 2011 Oct 19;12(10):R103

2011
C.G.M. Gadellaa-van Hooijdonk, M.J. Koudijs, E.P.J.G. Cuppen, P.J. van Diest, J.W.M. Martens, S. Sleijfer, J.H.M. Schellens, E.E. Voest en M.P.J.K. Lolkema

Van DNA-afwijkingen tot therapie: selectie voor geïndividualiseerde kankerbehandeling.

NTvO 2011, vol8

2011
Nijman IJ, Mokry M, van Boxtel R, Toonen P, de Bruijn E, Cuppen E.

Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples.

Nat Methods. 2010 Nov;7(11):913-5

2010